Ceftazidime and Ciprofloxacin in the prevention of infection in children under transplantation

Comparison of Ceftazidime and Ciprofloxacin as antimicrobial prophylaxis in pediatric undergoing Hematopoietic stem cell transplant patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120415009475N8

Enrollment

Registered

2020-08-04

Start date

2020-08-22

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neutropenic fever in pediatric Hematopoietic stem cell transplantation. Complications of bone marrow transplant

Interventions

Intervention 1: Intervention group: Ciprofloxacin ten milligrams three times a day as an injectable drug. Intervention 2: Intervention group: receive ceftazidime fifty milligrams three times a day as

Eligibility

Sex/Gender

All

Age

1 Months to 18 Years

Inclusion criteria

Inclusion criteria: pediatric patients undergo stem cell transplantation

Exclusion criteria

Exclusion criteria: Penicillin allergy Quinolone allergy Congenital Arrhythmia

Design outcomes

Primary

Measure	Time frame
Days without neutopenic fever from start of transplantation. Timepoint: Days. Method of measurement: Temperature measurement and White blood cell count.	—

Secondary

Measure	Time frame
Hospital stay. Timepoint: Days. Method of measurement: Counting.;White blood cell recovery time. Timepoint: Days. Method of measurement: The days until patient having two consecutive White blood cell counts above 1000 cells in milli Litre.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Bahador Mirrahimi

Shahid Beheshti University of Medical Sciences

mirrahimi@sbmu.ac.ir+98 21 2222 7020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026